CardioComm Solutions Responds to Cyber Security Incident
CardioComm Solutions Responds to Cyber Security Incident
Toronto, Ontario--(Newsfile Corp. - July 25, 2023) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announces a cyber security incident on the Company's servers.
安大略省多倫多-(Newsfile Corp.-2023年7月25日)-美國心臟通訊解決方案公司(TSXV：EKG)(“心電聯動“或”公司)，一家提供消費者心臟監測和醫療心電(“ECG”)軟體解決方案的全球醫療供應商，宣佈公司服務器上發生了一起網路安全事件。
The Company has launched a comprehensive investigation to fully ascertain the source and extent of any data breach and is working closely with KPMG-EGYDE, relevant authorities and third-party cybersecurity experts to support these efforts in accordance with industry best practices.
本公司已展開全面調查，以全面確定任何數據洩露的來源和程度，並正與畢馬威-EGYDE、相關當局和第三方網路安全專家密切合作，根據行業最佳實踐支持這些努力。
CardioComm's business operations will be impacted for several days and potentially longer depending how quickly the Company is able to restore its data and re-establishes its production server environments. There is no evidence that customers' health information was compromised as a result of this attack since CardioComm's software is designed to run on each client's own server environments. Further, CardioComm does not collect patient health information from its clients. The Company has initiated identity theft precautions should any employee personal information have been compromised to minimize the impact on its staff.
心臟通信公司的業務運營將受到數天甚至更長時間的影響，這取決於該公司恢復其數據和重建其生產服務器環境的速度。沒有證據表明客戶的健康資訊因這次攻擊而受到損害，因為心臟通信公司的軟體被設計為在每個客戶自己的服務器環境上運行。此外，心臟通訊公司不從其客戶那裡收集患者的健康資訊。如果任何員工的個人資訊被洩露，公司已啟動身分竊盜預防措施，以將對員工的影響降至最低。
The Company also provides an update respecting the Cease Trade Order (the "CTO") issued by the Ontario Securities Commission and the suspension of trading imposed by the TSX Venture Exchange due to the late filing of the Company's annual financial statements for the financial year ended December 31, 2022 (the "Financial Statements") and its management's discussion and analysis relating to the Financial Statements (collectively, the "Required Filings") before the prescribed deadline of May 1, 2023 (see the Company's press releases dated May 1, 2023 and May 10, 2023 for further details). Although unexpectedly delayed by the security incident, the Company continues to work with its auditor to finalize the Required Filings, which are anticipated to be filed prior to the end of the 90 day CTO term, following which the Company will apply for reinstatement for trading on the TSX Venture Exchange. The Company will provide updates as warranted.
公司還提供了關於安大略省證券委員會發布的停止交易令(“CTO”)和多倫多證券交易所因延遲提交公司截至2022年12月31日的財政年度財務報表(“財務報表”)而被多倫多證券交易所暫停交易的最新情況，以及管理層在規定的截止日期2023年5月1日之前與財務報表相關的討論和分析(統稱為“要求提交的財務報表”)的最新情況(詳情請參閱公司日期為2023年5月1日和2023年5月10日的新聞稿)。儘管安全事件意外推遲，但公司仍在繼續與其審計師合作，以最終確定所需的申報檔案，這些申報檔案預計將在90天的CTO期限結束前提交，之後公司將申請恢復在多倫多證券交易所創業板交易。公司將在保證的情況下提供更新。
To learn more about CardioComm's products and for further updates regarding HeartCheck ECG device integrations please visit the Company's websites at and .
欲瞭解更多有關HearoComm公司產品的資訊，以及有關HeartCheck心電設備集成的進一步更新，請訪問該公司的網站和。
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).
關於心通解決方案
心臟通訊解決方案公司的專利和專有技術用於記錄、觀看、分析和存儲心電，用於心臟病患者的診斷和管理。產品通過外部分銷網路和北美銷售團隊銷往世界各地。心臟通信解決方案公司已獲得國際標準化組織13485和國際標準化組織27001認證，符合美國國際藥品監督管理局的要求，並持有美國食品和藥物管理局和加拿大衛生部頒發的醫療器械許可和銷售許可證。
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com
欲瞭解更多資訊，請聯繫：
首席執行官艾蒂安·格裡馬
1-877-977-9425轉227
郵箱：Investor.Relationship@Hearocomsoltions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
前瞻性陳述
本新聞稿可能包含有關心臟通信解決方案公司的財務狀況、經營和業務結果以及心臟通信解決方案公司與這些專案有關的某些計劃和目標的前瞻性陳述和前瞻性資訊。這些陳述和資訊反映了管理層目前的信念，並以管理層目前掌握的資訊為基礎。就其性質而言，前瞻性陳述和前瞻性資訊涉及風險和不確定性，因為它們與事件有關，並取決於未來發生的情況，而且有許多因素可能導致實際結果和事態發展與這些前瞻性陳述和前瞻性資訊明示或暗示的情況大不相同。
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
在評估這些陳述時，讀者不應過分依賴前瞻性陳述和前瞻性資訊。除適用法律要求外，公司不承擔更新本新聞稿中包含的前瞻性陳述和前瞻性資訊的任何義務，包括但不限於國家文書51-102(持續披露義務).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。